Future of gMG Treatment
James F. Howard Jr, MD, shares thoughts on the future of the treatment of gMG, highlighting the renewed interest in the disease landscape.
Other FcRn Targeting Agents gMG
An expert neurologist reviews efficacy and safety data of rozanolixizumab, an FcRn-targeting agent approved for treatment of gMG, as well as how it differs from efgartigimod.
Subcutaneous Efgartigimod for Treatment of gMG
James F. Howard Jr, MD, discusses both intravenous and subcutaneous efgartigimod for the treatment of gMG.
Personalizing gMG Treatment
An expert neurologist comments on the need for generalized myasthenia gravis treatment to be tailored to the patient to alleviate symptoms without significant adverse effects.
Therapeutic Strategies in gMG
An expert reviews targeted therapies in generalized myasthenia gravis, highlighting complement and neonatal Fc receptors.
Considerations for Approaching the Management of gMG
An expert comments on the impact of factors such as disease course, antibody status, and patient adherence on the management of gMG.
Impact of Generalized Myasthenia Gravis (gMG) on Quality of Life
A physician expert discusses the socioeconomic burden of gMG on both the patient and the caregiver.
Unmet Needs and Future Directions in Myasthenia Gravis
James F. Howard Jr., MD, and Nicholas J. Silvestri MD, FAAN, deliver parting thoughts on the state of the myasthenia gravis treatment, focusing on current deficits and future prospects.
Investigational Agents for Myasthenia Gravis
Two subject matter experts discuss promising treatment methods and agents in the pipeline for patients with myasthenia gravis.
FcRns Inhibitors for the Treatment of Myasthenia Gravis
James F. Howard Jr., MD and Nicholas J. Silvestri MD, FAAN, discuss the efficacy and safety of FcRn inhibitors, as well as consider their role in the rapidly evolving treatment landscape.
Experts discuss the benefits of complement inhibitors in reducing symptoms of myasthenia gravis.
Recently FDA Approved Medications for Myasthenia Gravis
James F. Howard Jr., MD, and Nicholas J. Silvestri MD, FAAN, review the role of complement inhibitors and FcRn inhibitors in the management of myasthenia gravis.
Non-Pharmacological Approaches for to Myasthenia Gravis
Thought leaders review the role of non-pharmacological strategies to manage myasthenia gravis comorbidities.
Drugs to Avoid in Patients With Myasthenia Gravis
A comprehensive review of drugs to avoid when designing treatment plans for patients with myasthenia gravis.
Treatment Approaches in Special Populations with Myasthenia Gravis
Experts recommend approaches for special cases including ocular myasthenia gravis, pregnant patients and children with myasthenia gravis, and more.
Acute Exacerbation of Myasthenia Gravis
Recommendations from neurologists James F. Howard Jr., MD and Nicholas J. Silvestri MD, FAAN for addressing acute exacerbation in patients with myasthenia gravis.
Use of Thymectomy
Two subject matter experts discuss cases where a thymectomy is appropriate for treating patients with myasthenia gravis.
Use of AChEI and Immunosuppressives in Managing Symptoms
James F. Howard Jr., MD and Nicholas J. Silvestri MD, FAAN, share insights regarding acetylcholinesterase inhibitors and immunosuppressive therapy as first-line treatments for patients with myasthenia gravis.
Goals of Therapy and Patient Communication
Thought leaders offer practical advice on setting therapy goals for patients with myasthenia gravis, with an emphasis on patient inclusion.
Misdiagnosis Associated With Myasthenia Gravis and Importance of Multidisciplinary Teams
Expert panelists discuss misdiagnosis of myasthenia gravis and consider the question of whether this condition should be treated by community physicians.
Understanding and Diagnosing Myasthenia Gravis
James F. Howard Jr., MD and Nicholas J. Silvestri MD, FAAN discuss an overview of myasthenia gravis and important tools for diagnosis of myasthenia gravis.
2 Commerce Drive Cranbury, NJ 08512